USO 25230

BNT324-03 A Phase III, randomized, open-label trial of BNT324 versus docetaxel with prednisone/prednisolone in metastatic castration-resistant prostate cancer

Disease Types: Genitourinary Cancer Research

Eligibility Requirements:

• Subjects must have histological, pathological, and/or cytological
confirmation of prostate cancer that is progressive
• Subjects must have previously received at least one 1-2 prior ARPI in either
non-metastatic HSPC, mHSPC, non-metastatic CRPC, or mCRPC and had
progressive disease during or after at least 8 weeks of treatment
• Subjects must have ≥1 metastatic lesion
• Subjects with a positive 68Ga-PSMA-11 PET/CT scan may have received
prior 177Lu-PSMA or investigational PSMA-targeted radioligand therapy if
treatment was completed more than 8 weeks before trial dosing
• Subjects must have had prior orchiectomy and/or have ongoing ADT and a
castrate-level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L)
• Subjects that previously received an ADC with a topoisomerase inhibitor,
B7-H3 targeted therapy, or cytotoxic chemotherapy are excluded

For more information on this trial CLICK HERE .

Available at:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Suffolk (Harbour View)
• Virginia Beach (Princess Anne)
• Williamsburg